Pneumococcal Disease

Conjugate Vaccines May Be More Effective than Polysaccharide Vaccines in HIV Patients

Published in Vaccine Weekly, October 18th, 2000

Depending on HIV serotype, a 7-valent pneumococcal conjugate vaccine was more protective than a 23-valent polysaccharide vaccine in HIV infected adults, researchers in the United States found.

"HIV infected patients have increased risk for invasive pneumococcal disease and respond poorly to the polysaccharide vaccine as their immune status declines," stated D. Feikin and colleagues from the U.S. Centers for Disease Control, Georgia, and several universities across the United States. "In this double-blinded trial, we randomized adults with CD4 counts {{>=}}200 to receive placebo (PL), 70-valent conjugate (7V, CRM₁₉₇ carrier protein, Wyeth-Lederle), or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry